| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 21 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT NO. 2 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER, dated as of September 15, 2026 (this “Amendment No. 2”), is entered into by and between Insight Molecular Diagnostics Inc. (formerly known as Oncocyte Corporation... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Discussions with FDA advance toward expected marketing authorization for GraftAssureDx |
| 17 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This SECOND AMENDMENT TO THE INSIGHT MOLECULAR DIAGNOSTICS INC. AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (this “Amendment”), effective as of June 11, 2026, is made and entered into by Insight Molecular Diagnostics Inc., a Californ... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement |
| 30 Apr 2026 |
8-K: Other Events
Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at such place within or without the State of California as shall be fixed from time to time by the board of directors, and if no ... |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Submitted GraftAssureDxTM for kidney transplant rejection testing for FDA review on Wednesday, March 25 |
| 26 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”). Pursuant to the Agreement, Quest Diagnosti... |
| 12 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of February 10, 2026, between Insight Molecular Diagnostics Inc., a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (ea... |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure
Insight Molecular Diagnostics Inc. (the “Company”) intends, from time to time, to present, utilize, and/or at one or more meetings with investors or analysts a slide presentation, which is attached hereto as Exhibits 99.1. The Company un... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
On track to submit GraftAssureDx™ for FDA review by year-end |
| 02 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
THIS AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of September 29, 2025, by and between Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation (the “Company”), a California corporation located at... |
| 19 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 16, 2025, the Board of Directors (the “Board”) of Insight Molecular Diagnostics Inc. (the “Company”) and the Compensation Committee of the Board approved increases to the annual base salaries of (i) Joshua Riggs, the Company... |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
Transplant clinical trial has attracted leading transplant hospitals |
| 02 Jul 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 27, 2025, Insight Molecular Diagnostics Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) virtually via live webcast at https://web.lumiconnect.com/259974801. Present at the Annual Meeting v... |
| 17 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at such place within or without the State of California as shall be fixed from time to time by the board of directors, and if no ... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Q1 2025 pharma services revenue of $2.1 million, at 62% gross margin |
| 17 Apr 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by Oncocyte Corporation under Item 4.01 of its Form 8-K dated April 17, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other st... |
| 24 Mar 2025 |
8-K: Results of Operations and Financial Condition
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million |
| 10 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 4, 2025, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”), at the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved increases to the annual base salari... |
Loading...